Reviva Pharmaceuticals Holdings, Inc. Debt Conversion, Converted Instrument, Amount
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Debt Conversion, Converted Instrument, Amount of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-15.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2022-03-15
- Reviva Pharmaceuticals Holdings, Inc. debt conversion, converted instrument, amount for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Reviva Pharmaceuticals Holdings, Inc. debt conversion, converted instrument, amount for fiscal 2020 was $6.88M.
| Period end | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-15 |
| 2020-12-31 | $6.88M 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |